| Followers | 53 |
| Posts | 14434 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Sunday, October 09, 2016 6:52:33 AM
JL, no question that science marches on and although sometimes spends time going down a cul de sac, we learn more every century. We've learned much since the days of the old alchemists.
So hopefully, we find more answers about how to best treat COPD. As you describe to Babr, your experience with that facelift woman is anecdotal. There would be so many more details about her condition necessary to unravel what really happened for her to successfully dump the oxygen.
I have an anecdotal experience as well. Rather personal but just to show that it is difficult to extrapolate individual cases into generalizations about the population in general.
Approximately 8 year ago, my wife (who was sedentary, coffee and cigarettes for 35 years up till then) had gone outside after dinner for a smoke. She had been coughing a lot the last couple of days and complaining of "just a cold". She came back in the house and for the first time asked me to take her to the emergency room. After workup there, she was admitted, diagnosed with COPD and immediately put on oxygen. After a week she was released with a loud oxygen concentrator machine running 24/7 at home and a bunch of oxygen tanks in our dining room for she ever ventured out. She was defeated and depressed.
After seeing a lung doctor for the first time and learning various things about the disease (which she probably had for a long time) she slowly started to get herself on a very gradual regimen of trying to strengthen her leg muscles, etc. Long story short, within 3 months she was off oxygen entirely (No V) and a couple of years later, while on a cruise, climbed the thousand plus steps in Kotor. She has big limitations and her O2 level drops under strenuous conditions or altitude, but so far not required to get back on O2.
All that to say that in science anecdotes can lead to hypotheses and investigations (which is what you are saying in terms of recommending trying V) but it will require more rigorous investigations to know with some certainty how this particular disease responds.
So hopefully, we find more answers about how to best treat COPD. As you describe to Babr, your experience with that facelift woman is anecdotal. There would be so many more details about her condition necessary to unravel what really happened for her to successfully dump the oxygen.
I have an anecdotal experience as well. Rather personal but just to show that it is difficult to extrapolate individual cases into generalizations about the population in general.
Approximately 8 year ago, my wife (who was sedentary, coffee and cigarettes for 35 years up till then) had gone outside after dinner for a smoke. She had been coughing a lot the last couple of days and complaining of "just a cold". She came back in the house and for the first time asked me to take her to the emergency room. After workup there, she was admitted, diagnosed with COPD and immediately put on oxygen. After a week she was released with a loud oxygen concentrator machine running 24/7 at home and a bunch of oxygen tanks in our dining room for she ever ventured out. She was defeated and depressed.
After seeing a lung doctor for the first time and learning various things about the disease (which she probably had for a long time) she slowly started to get herself on a very gradual regimen of trying to strengthen her leg muscles, etc. Long story short, within 3 months she was off oxygen entirely (No V) and a couple of years later, while on a cruise, climbed the thousand plus steps in Kotor. She has big limitations and her O2 level drops under strenuous conditions or altitude, but so far not required to get back on O2.
All that to say that in science anecdotes can lead to hypotheses and investigations (which is what you are saying in terms of recommending trying V) but it will require more rigorous investigations to know with some certainty how this particular disease responds.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
